Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation

Kamar, 2006, Treatment of hepatitis C virus infection (HCV) after renal transplantation: Implications for HCV-positive dialysis patients awaiting a kidney transplant, Transplantation, 82, 853, 10.1097/01.tp.0000238898.14393.c9 Fabrizi, 2014, Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: Meta-analysis of clinical studies, J Viral Hepat, 21, 681, 10.1111/jvh.12276 Rostaing, 1995, Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients, Transplantation, 59, 1426, 10.1097/00007890-199505270-00012 2008, Kidney disease: improving global outcomes (KDIGO), Kidney Int Suppl, 109, S1 Kamar, 2003, Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: Effects on renal function and liver histology, Am J Kidney Dis, 42, 184, 10.1016/S0272-6386(03)00422-0 Kamar, 2004, Amantadine therapy in renal transplant patients with hepatitis C virus infection, J Clin Virol, 30, 110, 10.1016/j.jcv.2003.10.001 Calanca, 2007, Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone, J Clin Virol, 39, 54, 10.1016/j.jcv.2007.02.006 Kamar, 2003, Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation, J Am Soc Nephrol, 14, 2092, 10.1097/01.ASN.0000079613.81511.3C Sulkowski, 2014, Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection, N Engl J Med, 370, 211, 10.1056/NEJMoa1306218 Lawitz, 2014, Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: The COSMOS randomised study, Lancet, 384, 1756, 10.1016/S0140-6736(14)61036-9 Kowdley, 2014, Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis, N Engl J Med, 370, 1879, 10.1056/NEJMoa1402355 Afdhal, 2014, Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection, N Engl J Med, 370, 1483, 10.1056/NEJMoa1316366 Afdhal, 2014, Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection, N Engl J Med, 370, 1889, 10.1056/NEJMoa1402454 Forns, 2014, Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation, Hepatology, 10.1016/S0168-8278(14)60064-7 Charlton, 2015, Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation, Gastroenterology, 148, 108, 10.1053/j.gastro.2014.10.001 Curry, 2015, Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: An open-label study, Gastroenterology, 148, 100, 10.1053/j.gastro.2014.09.023 Kwo, 2014, An interferon-free antiviral regimen for HCV after liver transplantation, N Engl J Med, 371, 2375, 10.1056/NEJMoa1408921 Delabaudiere, 2014, Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation, Transpl Int, 28, 255, 10.1111/tri.12428 Bonacci, 2015, Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCV-decompensated cirrhosis: Viral eradication and removal from the liver transplant waiting list, Transpl Int, 10.1111/tri.12622 Bedossa, 1996, An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group, Hepatology, 24, 289, 10.1002/hep.510240201 Ganne-Carrie, 2006, Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases, Hepatology, 44, 1511, 10.1002/hep.21420 Morales, 2015, Hepatitis C and its impact on renal transplantation, Nat Rev Nephrol, 11, 172, 10.1038/nrneph.2015.5 Thervet, 1994, Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients, A pilot study. Transplantation, 58, 625 Alric, 2004, Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN, Am J Kidney Dis, 43, 617, 10.1053/j.ajkd.2003.11.020 Kamar, 2004, Ribavirin pharmacokinetics in renal and liver transplant patients: Evidence that it depends on renal function, Am J Kidney Dis, 43, 140, 10.1053/j.ajkd.2003.09.019 Wolffenbuttel, 2004, Cyclosporine pharmacokinetics in anti-HCV+ patients. Clin Transplant, 18, 654